UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) and BRAF V600E mutation have a poor prognosis, with a median progression-free survival (PFS) of only 5–7 months after initial therapy. The current standard first-line chemotherapy for these patients includes FOLFOX or FOLFIRI plus bevaciz...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Yi-Chien, Chang, Tsung-Kun, Su, Wei-Chih, Huang, Ching-Wen, Tsai, Hsiang-Lin, Chen, Yen-Cheng, Li, Ching-Chun, Chen, Po-Jung, Yin, Tzu-Chieh, Ma, Cheng-Jen, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972843/
https://www.ncbi.nlm.nih.gov/pubmed/33777142
http://dx.doi.org/10.1155/2021/6686517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972843/
https://www.ncbi.nlm.nih.gov/pubmed/33777142
http://dx.doi.org/10.1155/2021/6686517

Ejemplares similares